235 related articles for article (PubMed ID: 12473600)
1. Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer.
McCarthy NJ; Yang X; Linnoila IR; Merino MJ; Hewitt SM; Parr AL; Paik S; Steinberg SM; Hartmann DP; Mourali N; Levine PH; Swain SM
Clin Cancer Res; 2002 Dec; 8(12):3857-62. PubMed ID: 12473600
[TBL] [Abstract][Full Text] [Related]
2. Changes in microvessel density as assessed by CD34 antibodies after primary chemotherapy in human breast cancer.
Bottini A; Berruti A; Bersiga A; Brizzi MP; Allevi G; Bolsi G; Aguggini S; Brunelli A; Betri E; Generali D; Scaratti L; Bertoli G; Alquati P; Dogliotti L
Clin Cancer Res; 2002 Jun; 8(6):1816-21. PubMed ID: 12060622
[TBL] [Abstract][Full Text] [Related]
3. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
[TBL] [Abstract][Full Text] [Related]
4. Commentary re: N. J. McCarthy et al., microvessel density, expression of estrogen receptor alpha, MIB-1, p53 and c-erbB-2 in inflammatory breast cancer. Clin. Cancer Res., 8: 3857-3862, 2002.
Colpaert CG; Vermeulen PB; Dirix LY; Van Marck EA
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3815-6; author reply 3816. PubMed ID: 14506176
[No Abstract] [Full Text] [Related]
5. Prognostic significance of the co-expression of p53 and c-erbB-2 proteins in breast cancer.
Nakopoulou LL; Alexiadou A; Theodoropoulos GE; Lazaris AC; Tzonou A; Keramopoulos A
J Pathol; 1996 May; 179(1):31-8. PubMed ID: 8691341
[TBL] [Abstract][Full Text] [Related]
6. Is triple negative a prognostic factor in breast cancer?
Nishimura R; Arima N
Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
[TBL] [Abstract][Full Text] [Related]
7. Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'.
Charafe-Jauffret E; Tarpin C; Bardou VJ; Bertucci F; Ginestier C; Braud AC; Puig B; Geneix J; Hassoun J; Birnbaum D; Jacquemier J; Viens P
J Pathol; 2004 Mar; 202(3):265-73. PubMed ID: 14991891
[TBL] [Abstract][Full Text] [Related]
8. Persistent E-cadherin expression in inflammatory breast cancer.
Kleer CG; van Golen KL; Braun T; Merajver SD
Mod Pathol; 2001 May; 14(5):458-64. PubMed ID: 11353057
[TBL] [Abstract][Full Text] [Related]
9. p53 in breast cancer. Its relation to histological grade, lymph-node status, hormone receptors, cell-proliferation fraction (ki-67) and c-erbB-2. Immunohistochemical study of 153 cases.
Sirvent JJ; Salvadó MT; Santafé M; Martínez S; Brunet J; Alvaro T; Palacios J
Histol Histopathol; 1995 Jul; 10(3):531-9. PubMed ID: 7579801
[TBL] [Abstract][Full Text] [Related]
10. Differences in prognostic molecular markers between women over and under 45 years of age with advanced ovarian cancer.
Chan JK; Loizzi V; Magistris A; Lin F; Rutgers J; Osann K; Disaia PJ; Berman ML
Clin Cancer Res; 2004 Dec; 10(24):8538-43. PubMed ID: 15623636
[TBL] [Abstract][Full Text] [Related]
11. Prospective studies of p53 and c-erbB-2 expression in relation to clinicopathological parameters of human ductal breast cancer in the second stage of clinical advancement.
Bebenek M; Bar JK; Harlozinska A; Sedlaczek P
Anticancer Res; 1998; 18(1B):619-23. PubMed ID: 9568187
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory breast cancers in Tunisia and France show similar immunophenotypes.
Charafe-Jauffret E; Mrad K; Intidhar Labidi S; Ben Hamida A; Ben Romdhane K; Ben Abdallah M; Ginestier C; Esterni B; Birnbaum D; Ben Ayed F; Xerri L; Viens P; Mezlini A; Jacquemier J
Breast; 2007 Aug; 16(4):352-8. PubMed ID: 17360185
[TBL] [Abstract][Full Text] [Related]
13. Id-1 overexpression in invasive ductal carcinoma cells is significantly associated with intratumoral microvessel density in ER-negative/node-positive breast cancer.
Jang KS; Han HX; Paik SS; Brown PH; Kong G
Cancer Lett; 2006 Dec; 244(2):203-10. PubMed ID: 16469432
[TBL] [Abstract][Full Text] [Related]
14. Biopsy specimen microvessel density is a useful prognostic marker in patients with T(2-4)M(0) esophageal cancer treated with chemoradiotherapy.
Hironaka S; Hasebe T; Kamijo T; Ohtsu A; Boku N; Yoshida S; Saitoh H; Ochiai A
Clin Cancer Res; 2002 Jan; 8(1):124-30. PubMed ID: 11801548
[TBL] [Abstract][Full Text] [Related]
15. Do prognostic marker studies on core needle biopsy specimens of breast carcinoma accurately reflect the marker status of the tumor?
Jacobs TW; Siziopikou KP; Prioleau JE; Raza S; Baum JK; Hayes DF; Schnitt SJ
Mod Pathol; 1998 Mar; 11(3):259-64. PubMed ID: 9521472
[TBL] [Abstract][Full Text] [Related]
16. Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding.
Van Laere SJ; Van der Auwera I; Van den Eynden GG; Elst HJ; Weyler J; Harris AL; van Dam P; Van Marck EA; Vermeulen PB; Dirix LY
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3249-56. PubMed ID: 16740744
[TBL] [Abstract][Full Text] [Related]
17. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.
Johnston S; Trudeau M; Kaufman B; Boussen H; Blackwell K; LoRusso P; Lombardi DP; Ben Ahmed S; Citrin DL; DeSilvio ML; Harris J; Westlund RE; Salazar V; Zaks TZ; Spector NL
J Clin Oncol; 2008 Mar; 26(7):1066-72. PubMed ID: 18212337
[TBL] [Abstract][Full Text] [Related]
19. Relationship between hormonal receptors, HER-2, p53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients.
Kariya S; Ogawa Y; Nishioka A; Moriki T; Ohnishi T; Ito S; Murata Y; Yoshida S
Radiat Med; 2005 May; 23(3):189-94. PubMed ID: 15940066
[TBL] [Abstract][Full Text] [Related]
20. Apocrine carcinomas of the breast in Turkish women: hormone receptors, c-erbB-2 and p53 immunoexpression.
Kaya H; Bozkurt SU; Erbarut I; Djamgoz MB
Pathol Res Pract; 2008; 204(6):367-71. PubMed ID: 18342452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
